Physician profile
Mona Khater
NPI 1992763940
$779.40
in general payments reported to CMS, 2019-2025
15 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $72.37 · 2023: $242 · 2024: $193 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208.01 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $96.35 | 2023-2025 | |
| Amgen INC. | $93.88 | 2022-2024 | Repatha, Otezla, Uplizna |
| Glaxosmithkline, LLC. | $88.21 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $62.02 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $49.55 | 2024-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $32.96 | 2024 | Nexletol |
| Rhythm Pharmaceuticals, INC. | $22.04 | 2023 | Imcivree |
| Biohaven Pharmaceutical Holding Company LTD. | $21.23 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.64 | 2023 | Quviviq |
| Abbott Laboratories | $18.07 | 2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $17.85 | 2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $17.47 | 2025 | Voquezna |
| Astellas Pharma US INC | $16.46 | 2023 | Myrbetriq |
| Krystal Biotech INC | $14.66 | 2023 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Khater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.